key: cord-1042504-aiptqdoh
authors: Frías-De-León, María Guadalupe; Pinto-Almazán, Rodolfo; Hernández-Castro, Rigoberto; García-Salazar, Eduardo; Meza-Meneses, Patricia; Rodríguez-Cerdeira, Carmen; Arenas, Roberto; Conde-Cuevas, Esther; Acosta-Altamirano, Gustavo; Martínez-Herrera, Erick
title: Epidemiology of Systemic Mycoses in the COVID-19 Pandemic
date: 2021-07-13
journal: J Fungi (Basel)
DOI: 10.3390/jof7070556
sha: 16727557ceb30f9b6fc513361cc6585fee15560c
doc_id: 1042504
cord_uid: aiptqdoh

The physiopathologic characteristics of COVID-19 (high levels of inflammatory cytokines and T-cell reduction) promote fungal colonization and infection, which can go unnoticed because the symptoms in both diseases are very similar. The objective of this work was to study the current epidemiology of systemic mycosis in COVID-19 times. A literature search on the subject (January 2020–February 2021) was performed in PubMed, Embase, Cochrane Library, and LILACS without language restrictions. Demographic data, etiological agent, risk factors, diagnostic methods, antifungal treatment, and fatality rate were considered. Eighty nine publications were found on co-infection by COVID-19 and pneumocystosis, candidiasis, aspergillosis, mucormycosis, coccidioidomycosis, or histoplasmosis. In general, the co-infections occurred in males over the age of 40 with immunosuppression caused by various conditions. Several species were identified in candidiasis and aspergillosis co-infections. For diagnosis, diverse methods were used, from microbiological to molecular. Most patients received antifungals; however, the fatality rates were 11–100%. The latter may result because the clinical picture is usually attributed exclusively to SARS-CoV-2, preventing a clinical suspicion for mycosis. Diagnostic tests also have limitations beginning with sampling. Therefore, in the remainder of the pandemic, these diagnostic limitations must be overcome to achieve a better patient prognosis.

SARS-CoV-2 is a betacoronavirus that causes the "2019 coronavirus disease" . Since the World Health Organization (WHO) declared a pandemic in March 2020, the world has been facing a health crisis that has involved significant challenges in diagnosing, treating, and preventing COVID-19 and its complications. As of 21 March 2021, it has affected 122,524,424 people in 222 countries resulting in the deaths of 2,703,620 individuals, showing an overall fatality rate of 2.2% [1] . The clinical course and progression of SARS-CoV-2 infection is variable and can lead to respiratory failure [2] . Clinical presentations of COVID-19 include fever (≥38 • C), cough, shortness of breath, loss of smell, chills, headache, and joint pain, among the most frequently reported. In most cases, the disease is asymptomatic or with mild to moderate symptomatology (80-85%) [3] . However, the disease can evolve to more severe clinical pictures in some patients, putting their lives at risk.

Reports indicate that the overall host state and the presence of comorbidities facilitate the spread of the virus and tropism of target organs with angiotensin-converting enzyme 2 (ACE2) receptors and increased production of interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF)-α in severe cases [2] . In the case of the disease requiring hospitalization, it is characterized by pneumonia, lymphopenia, and cytokine release syndrome (CRS), which trigger an exaggerated immune response that causes damage at the local and systemic level. The previous occurs because, after the virus enters the cells and releases its genetic material (RNA), it is recognized by innate immunity receptors located intracellularly. Receptors such as the Toll 7 (TLR7), retinoic acid-inducible gene I (RIG-1), and melanoma differentiationassociated protein 5 (MDA-5), activate a signaling cascade, leading to the expression of interferon (IFN) type I (α and β), the objective of which is to interfere with viral replication. On the other hand, viral antigens can be processed by antigen-presenting cells through their major histicompatibility complex (MHC)-I to T cell receptor (TCR) of T CD8+ lymphocyte, which involves releasing their proteolytic enzymes (cytotoxicity). At the same time, the cytokine storm begins (an increase of IL-1B, IL-6, IL-7, IL-8, IL-9, IL-10, and TNF-α [2] [3] [4] .

In mild pneumonia, patients may be asymptomatic or have at least one of the following symptoms: fever (constant or intermittent), dry cough, sore throat, headache, myalgia, tiredness, or diarrhea. However, they do not present dyspnea nor hypoxia [3] . Although in most patients (81%), the course of the disease is mild, some develop severe pneumonia, characterized by the acute respiratory distress syndrome (ARDS), refractory hypoxemia, and dyspnea. More than 50% experience lung damage radiologically characterized by the presence of bilateral ground-glass opacities. In some cases, patients also develop damage and dysfunction of the extrapulmonary system, such as alterations in the hematological and digestive system, risk of sepsis, and septic shock, with a high mortality rate [4] . Some of these patients present patchy bilateral opacities in the lungs, leukopenia or lymphopenia, and increased serum levels of alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), creatine kinase myocardial band (CK-MB), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) [5] .

Approximately 5 to 30% of COVID-19 patients have been reported to become critically ill, require mechanical ventilation, and admission to the Intensive Care Unit (ICU) [2, 3] , which constitutes a risk factor for the development of co-infections with other bacterial, viral, or fungal pathogens. SARS-CoV-2 infection is characterized by a cytokine storm involving increased inflammatory proteins (TNF-α, IL-6, IL-2R) and decreased anti-inflammatory proteins. The latter contributes to lung pathology and lymphopenia development (drastic decrease in T cells, CD4+ and CD8+) in patients admitted to the ICU [5] . Lymphopenia in patients with severe COVID-19 is a clinical situation that increases the risk of severe fungal infections by different fungal genera, such as Pneumocystis, Candida, and Aspergillus, as T cells are the second most crucial line of defense against mycoses [6, 7] .

Fungal co-infections in COVID-19 patients is not a surprising situation. There are precedents that viral pneumonia, such as H1N1 and H7N9 influenza, can have co-infections caused by fungi and bacteria, and even other viruses [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . During the outbreak of severe acute respiratory syndrome (SARS) detected in Guangdong, China, in November 2002, that subsequently spread to more than 30 countries, a series of autopsy cases were reported, which evidenced invasive fungal infection compatible with invasive aspergillosis in 10% of cases [18] . Interestingly, all infected patients were treated with high doses of corticosteroids, possibly resulting in immunosuppression that facilitated the establishment of mycoses. Another autopsy study of individuals who died of SARS confirmed fungal co-infection with the isolation of Aspergillus sp. and Mucor sp. in the upper respiratory tract and lungs. A case with multiple Aspergillus abscesses in different organs was also reported [19] . With this background, the co-infection scenario is expected to be similar in SARS-CoV-2 pneumonia.

This work analyzes the epidemiology of fungal co-infections in COVID-19 patients based on the review of publications on the subject during the first year of the pandemic.

A thorough search of publications on the subject was performed from January 1st, 2020, to 28 February 2021. The search was conducted on PubMed, Embase, Cochrane Library, and LILACS. The search words used were "fungi" OR "fungus" OR "fungal infection" OR "invasive fungal diseases" OR "pneumocystis" OR "candidiasis" OR "aspergillosis" OR "mucor" OR "histoplasmosis" OR "coccidioidomycosis" OR "co-infection" OR "secondary infection" AND "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV" OR "2019 novel coronavirus" without language restrictions. Cases caused by Cryptococcus, Fusarium, Saccharomyces, and other fungi were excluded from the study due to the low number of reports. The review was performed based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) (Figure 1 ). 

During the COVID-19 pandemic, 13 publications have reported a total of 24 confirmed cases of co-infection with SARS-CoV-2 and P. jirovecii (Table 1) . This co-infection has occurred in both men and women, in the age range of 11-83 years, predominantly in males over 40 years of age [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . The main risk factor for developing co-infection with Pneumocystis was HIV infection with low CD4+ count, followed by immunosuppressive treatments, lymphopenia, and autoimmune disease (anti-melanoma differentiation-associated gene 5 juvenile dermatomyositis) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Seven of these cases did not identify a typical risk factor for pneumocystosis [20] . The fungal presence was confirmed in 22 cases through different methods, such as PCR, high-performance sequencing, detection of β-D-glucan in serum, and staining techniques (Grocott and direct fluorescent antibody stain) [20] [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] [32] . Treatment of pneumocystosis in COVID-19 patients was trimethoprim-sulfamethoxazole [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . However, one patient presented intolerance to this medication, so he was treated with clindamycin [26] . In five cases, prednisone/prednisolone was added to treatment with trimethoprim-sulfamethoxazole [21, 24, 27, 28, 32] . In one case, the patient was successfully treated with caspofungin acetate [23] . The fatality rate of COVID-19 and pneumocystosis was 33.3% [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . 

In the first year of the COVID-19 pandemic, 29 articles on co-infection by SARS-CoV-2 and Candida spp. have been published (Table 2 ). Co-infections by Candida have been observed in both women and men, but predominantly in men over the age of 40 . The predisposing factors of candidiasis were multiple, including mechanical ventilation, placement of a central venous catheter, diabetes mellitus, antibiotics treatment, hospitalization time, anti-inflammatory treatment, and cancer . Other less common risk factors were asthma, HIV, and surgery, among others [34] [35] [36] 38, 41, 45, [47] [48] [49] [50] 52, 56, 60] . The diagnosis was performed through culture, PCR, sequencing, and MALDI-TOF [33] [34] [35] [36] [37] . The most identified pathogen was C. albicans, followed by C. glabrata, C. parapsilosis, C. tropicalis, C. auris, C. krusei, C. lusitaniae, C. inconspicua, C. dubliniensis, C. orthopsilosis, Candida spp. and non-albicans Candida . Patient treatment included azole antifungal agents (fluconazole, voriconazole, isavuconazole), echinocandins (caspofungin, anidulafungin, micafungin), and polyenes (amphotericin B, nystatin) [33] [34] [35] 40, [42] [43] [44] [46] [47] [48] [51] [52] [53] [54] 56, 59] . It should be noted that nystatin was used for the treatment of a patient with oropharyngeal candidiasis [43] . Despite antifungal treatment, the fatality rate among patients with COVID-19 and candidiasis oscillated between 11 and 100% . 

During the first year of the COVID-19 pandemic, 33 articles reporting aspergillosis co-infection in patients with COVID-19 have been published (Table 3 ). The most frequent causal agent was A. fumigatus, followed by A. flavus, Aspergillus spp. A. niger, A. terreus, A. lentulus, A. nidulans, A. awamori, A. penicillioides, and A. citrinoterreus [23, 56, . The most used diagnostic methods were cultivation, galactomannan and (1,3)-β-D-glucan detection, MALDI-TOF, histopathology, serological tests, PCR, and sequencing [23, 56, . It should be noted that in some of the A. fumigatus isolates, the TR34/L98H mutation in the Cyp51A gene was detected, which is associated with environmental azole resistance to antifungal agents [78, 83] . Caspofungin, voriconazole, amphotericin B, anidulafungin, posaconazole, itraconazole, fluconazole or isavuconazole were used in antifungal treatment [23, 56, [62] [63] [64] 66, 67, [69] [70] [71] [72] 74, [76] [77] [78] [79] [80] [81] [82] [84] [85] [86] [87] [88] [89] [90] .

The fatality rate in cases of Aspergillus co-infection with SARS-CoV-2 was between 13% and 100% [23, 56, . The affected patients were mainly men between 42 and 87 years of age [23, 56, . The reported predisposing risk factors for the mycosis progression were diverse, including treatment with corticosteroids or immunosuppressants, hospitalization in the ICU, diabetes mellitus, hypertension, obesity, invasive mechanical ventilation, neoplasms, chronic obstructive pulmonary disease (COPD), asthma, and kidney disease [23, 56, . 

In this study, nine publications of mucormycosis co-infection with COVID-19 were found (Table 4) . Except for one case [93] , all occurred in men in the age range of 24-86 years [93] [94] [95] [96] [97] [98] [99] [100] [101] . The predominant clinical form of mucormycosis was the rhinoorbital, followed by the pulmonary [93] [94] [95] [96] [97] [98] [99] [100] [101] . Only one case of each of the gastrointestinal [95] and rhinocerebral conditions was reported [93] . Among the main predisposing factors were diabetes mellitus, ketoacidosis, glucocorticoid use, or broad-spectrum antibiotics. Additional predisposing factors for lung mucormycosis were also reported, such as systemic high blood pressure, end-stage kidney disease, and ischemic cardiomyopathy [93] [94] [95] [96] [97] [98] [99] [100] [101] . The mycosis diagnosis was based mainly on histopathological analysis and culture [95] [96] [97] [98] [99] 101] . In two cases, the clinical picture and the magnetic resonance imaging (MRI) were considered alone [93, 94] , whereas in one case, PCR and sequencing were used to detect and identify the pathogen [100] . The etiological agents in decreasing order were Mucor spp., Rhizopus microsporus, Rhizopus spp., and Lichteimia spp. [96] [97] [98] [99] [100] . In 36% of cases, the fungus was not identified [93] [94] [95] 101] . Although the antifungal treatment included amphotericin B and isavuconazole, only 50% of patients showed clinical improvement [93, 94, [96] [97] [98] [99] 101] . The fatality rate was 50% [93] [94] [95] [96] [97] [98] [99] [100] [101] . 

Information on endemic fungal co-infections with SARS-CoV-2 is scarce. Only five cases have been published so far, two of COVID-19 and coccidioidomycosis in California, United States [102, 103] , and three of COVID-19 and histoplasmosis in Rio Grande, Southern Brazil, and Buenos Aires, Argentina [104] [105] [106] (Table 5 ). Coccidioidomycosis co-infections were caused by C. immitis [102, 103] . They occurred in a man and a woman, both 48 years of age, with the main predisposing factor of residing in endemic areas [102, 103] . The diagnosis was established with serological test results, and fluconazole was administered as an antifungal treatment. Both patients showed clinical improvement [102, 103] .

Histoplasmosis co-infections were caused by H. capsulatum and affected two women and one man in the range between 36 and 43 years of age [104] [105] [106] . Predisposing factors were HIV with CD4+ count < 200 cells/mm 3 and residing in endemic areas [104] [105] [106] . The diagnosis in these cases was performed through staining methods (Gomori-Grocott, Wright, and Giemsa), blood culture, and antigen detection in urine and serum [104] [105] [106] . Antifungal treatment in COVID-19 patients with histoplasmosis was itraconazole and amphotericin B deoxycholate, which noticeably improved patients' clinical state [104] [105] [106] . 

To date, there is no specific treatment for patients with COVID-19. However, in severe cases, high-dose systemic glucocorticoids are administered as it has been observed that they improve patient survival. Broad-spectrum antibiotics are also used [96] . The latter, in addition to the specific physiopathologic characteristics of COVID-19, such as the cytokine storm and reduced T-cell levels, favor fungal co-infections [94, 95, 101, 107] . However, reports of fungal co-infections in COVID-19 patients are scarce, probably because fungal lung infections, such as pneumocystosis, aspergillosis, histoplasmosis, and coccidioidomycosis, can be mistaken for SARS-CoV-2 infection.

Furthermore, they might be unnoticed because the symptoms in both diseases are very similar, including fever, dry cough, dyspnea, myalgia, and headache [7, 103] . There are no pathognomonic radiographic or tomographic findings that can differentiate a COVID-19 pneumopathy from a fungal infection [108] . These facts undoubtedly limit proper patient therapeutic management, which can lead to fatal outcomes, as shown by the few reports we present in this work, where the fatality rate ranges from 11 to 100% (Tables 1-5 ). This situation poses three new challenges related to the diagnosis of fungal infections that will have to be overcome in the remainder of the pandemic.

In the first challenge, it is crucial that, in the case of evidence of fungal co-infection in COVID-19 patients, the clinical picture is not attributed exclusively to SARS-CoV-2 infection, particularly in severe cases. While many of the secondary infections in these patients are caused by bacteria or viruses, it is vital to not forget about fungi, particularly those with clinical pictures virtually indistinguishable from SARS-CoV-2 pneumonia, like P. jirovecii. In this sense, healthcare workers must consider the medical history and epidemiological data, as they may be key to establishing clinical suspicion and directing diagnosis by selecting appropriate laboratory or cabinet tests.

The second challenge is related to diagnostic tests. The conventional tests that identify a fungal pathogen and confirm a mycosis diagnosis have different limitations, such as the time required to obtain a result or the impossibility of determining the fungus at the species level. The latter is utterly important, especially in mycosis caused by different species, particularly from the genera Candida, Aspergillus, and the order Mucorales. It is worth mentioning that new species have been identified, and many species that had not previously been associated with infections in humans are now recognized as pathogenic within these fungal groups. Further, many of these new species may have different susceptibility to the antifungals of choice for mycosis treatment, for example, we can cite C. auris and Aspergillus section Fumigati. While it is true that the limitations of conventional diagnostic tests have been gradually overcome with the development and implementation of different tests, particularly molecular ones, not all tests are available in intrahospital laboratories due to the lack of adequate infrastructure [91] .

Diagnosing mycoses with molecular techniques is often complicated because they require trained staff. It is also impractical to routinely analyze multiple samples. The use of PCR and other molecular methods provides limited detection and identification due to the presence of inhibitors in clinical samples. Such inhibitors can lead to underestimating fungus at different levels, from the extraction process to the amplification of nucleic acids. As for antigen detection, it is not always specific as there is potential antigenic crossreactivity, which would prevent fungal identification [109] .

The third challenge related to diagnostic tests is sample collection. For example, for COVID-19-associated pulmonary aspergillosis diagnosis, the sample must be collected from a bronchial washing that can generate aerosols representing a source of infection for healthcare personnel [62, 75, 110, 111] . Another critical complication in diagnosis is the lack of algorithms and standardized diagnostic methods since the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG) criteria are not specific for aspergillosis. For this reason, in an effort to establish a timely diagnosis, the AspICU algorithm for non-immunocompromised patients has been modified.

Overcoming these challenges will allow identification of cases of co-infections caused by SARS-CoV-2 and fungi, and enable definition of risk factors, affected populations, species distribution, and its antifungal profile.

Treatments reported in the revised literature fail to mention antifungal effectiveness as it is unknown whether the reported mortality was due to the stage of the disease per se or the fungal infection. In addition, treatment depends on the adequate diagnosis, which is complicated, as already mentioned. Thus, by not diagnosing the fungi properly, the correct treatment may not be given, and therefore it may not be effective.

It is important to mention that this work has limitations. This study did not include mycoses that were either reported just once, like fusariosis or caused by fungi that have rarely been associated with human infections, like Saccharomyces cerevisiae. Another limitation is that, unfortunately, not all fungal infections developed in COVID-19 patients have been reported in the literature. It should be noted that most references included in this study come from non-American countries, even though America has been the continent most affected by the pandemic. It is highly likely that fungal co-infections have occurred but have not been detected. It is our hope that the information presented in this study may serve as an alert for health workers to be aware of possible fungal co-infections in COVID-19 patients and the challenges posed by diagnosis. We also hope to remind them of the relevance of establishing acceptable infection control measures, prophylaxis, and adequate antifungal therapies. 

WHO. WHO Coronavirus (COVID-19) Dashboard. Available online

Clinical features of patients infected with 2019 novel coronavirus in

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention

The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies

Lymphopenia during the COVID-19 infection: What it shows and what can be learned

Fungal co-infection in COVID-19 patients: Should we be concerned?

Systemic mycoses: A potential alert for complications in COVID-19 patients

Isolation of Aspergillus in three 2009 H1N1 influenza patients

Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients

Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study

Invasive aspergillosis associated with severe influenza infection. Open Forum

Influenza-associated aspergillosis in critically ill patients

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study

Invasive pulmonary aspergillosis complicating severe influenza: Epidemiology, diagnosis and treatment

Case report: Disseminated aspergillosis complicating influenza

Intensive care management of influenzaassociated pulmonary aspergillosis

Invasive pulmonary aspergillosis in adults with avian influenza A (H7N9) pneumonia in China: A retrospective study

Pulmonary pathology of severe acute respiratory syndrome in Toronto

Fatal aspergillosis in a patient with SARS who was treated with corticosteroids

The presence of Pneumocystis jirovecii in critically ill patients with COVID-19

Concurrent COVID-19 and Pneumocystis jirovecii pneumonia in a severely immunocompromised 25-year-old patient

COVID-19-related respiratory failure and lymphopenia do not seem associated with pneumocystosis

A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab

Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: A diagnostic dilemma in HIV

Pneumocystis jirevocii and SARS-CoV-2 co-infection: A common feature in transplant recipients?

The diagnostic trap occurred in two COVID-19 cases combined Pneumocystis pneumonia in patient with

Diagnóstico simultáneo y evolución favorable de infección por Pneumocystis jirovecii, SARS-COV-2 y HIV avanzada

Pneumocystis jirovecii Pneumonia and SARS-CoV-2 co-infection in newly diagnosed HIV-1 infection

A Case of COVID-19 and Pneumocystis jirovecii coinfection

COVID-19 and Pneumocystis jirovecii pneumonia: Back to the basics

Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: A case report

Pneumocystis and severe acute respiratory syndrome coronavirus 2 coinfection: A case report and review of an emerging diagnostic dilemma

Successful management of the first reported case in Austria of COVID-19 with ARDS

Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids?

Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic

Co-infection with respiratory pathogens among COVID-2019 cases

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan

Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: A retrospective cohort study

Candida auris: A latent threat to critically ill patients with COVID-19

Predictors of severity and co-infection resistance profile in COVID-19 patients: First report from upper Egypt

Multidrug-resistant Candida auris infections in critically Ill coronavirus disease patients

Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: An increased risk for candidemia?

Detection of SARS-CoV-2 and other infectious agents in lower respiratory tract samples belonging to patients admitted to intensive care units of a tertiary-care hospital

Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect

Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically Ill patients: One step back in antimicrobial stewardship? Microorganisms

Panechinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: A fatal case report

Bloodstream infections in critically ill patients with COVID-19

COVID-BioB Study Group. Candidemia in COVID-19 patients: Incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls

First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon

Outbreak of Candida auris infection in a COVID-19 hospital in Mexico

COVID-19 associated invasive candidiasis

Barbolla-Díaz, I. Delayed Candida costochondritis and spondylitis in a post-COVID-19 patient previously treated with corticosteroids, antibiotics, and tocilizumab

Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Candida auris outbreak in a COVID-19 specialty care unit-Florida

COVID-19 in patients with hematologic-oncologic risk factors: Complications in three patients

Fungemia in COVID-19 ICU patients, a single medical center experience

Pulmonary pathology of COVID-19 following 8 weeks to 4 months of severe disease: A report of three cases, including one with bilateral lung transplantation

Epidemiology and mycology of candidemia in non-oncological medical intensive care unit patients in a tertiary center in the united states: Overall analysis and comparison between non-COVID-19 and COVID-19 cases

Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis

Aspergillosis complicating severe coronavirus disease

Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: A case report

Confirmed invasive pulmonary aspergillosis and COVID-19: The value of postmortem findings to support antemortem management

COVID-19-associated pulmonary aspergillosis: A prospective single-center dual case series

COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report

COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan

Dynamic Immune Response Profiles and Recovery of a COVID-19 Patient with Coinfection of Aspergillus fumigatus and Other Baseline Diseases: A Case Report

Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report

Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature

Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient

Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran

Fungal infection during COVID-19: Does Aspergillus mean secondary invasive aspergillosis?

Invasive pulmonary aspergillosis and hyperthermia in an immunocompetent patient with COVID-19

SARS-CoV-2 Working Group. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital

Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination

Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU

Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia

Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City

Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: A retrospective cohort study in light of antibiotic stewardship

Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU-A case report

SARS-CoV-2 and Aspergillus section Fumigati coinfection in an immunocompetent patient treated with corticosteroids

Fungal Balls" Complicating COVID-19

Ventilatorassociated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina

Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient

Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

COVID-19 associated invasive pulmonary aspergillosis: Diagnostic and therapeutic challenges

COVID-19-associated invasive aspergillosis: Data from the UK national mycology reference laboratory

Frequency of Positive Aspergillus Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the ICU

Mucormycosis with orbital compartment syndrome in a patient with COVID-19

Rhino-Orbital Mucormycosis Associated with COVID-19

Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: A case report

Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature

Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol. Case Rep

A Case of Fatal Rhino-Orbital Mucormycosis Associated with New Onset Diabetic Ketoacidosis and COVID-19

A challenging complication following SARS-CoV-2 infection: A case of pulmonary mucormycosis

Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy

Mucor in a Viral Land: A Tale of Two Pathogens

An Acute Pulmonary Coccidioidomycosis Coinfection in a Patient Presenting with Multifocal Pneumonia with COVID-19

The Coincidence of 2 Epidemics, Coccidioidomycosis and SARS-CoV-2: A Case Report

COVID-19-Associated Histoplasmosis in an AIDS Patient

COVID-19 Associated with AIDS-Related Disseminated Histoplasmosis: A Case Report

Covid-19) in a Patient with Disseminated Histoplasmosis and HIV-A Case Report from Argentina and Literature Review

COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19

When pneumonia is not COVID-19 Cuando la neumonía no es COVID-19

Molecular approaches to diagnosing and managing infectious diseases: Practicality and costs

Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, it pours

COVID-19 associated pulmonary aspergillosis (CAPA)-From immunology to treatment

The authors declare no conflict of interest.